BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
$9,88
Prezzo · Ago 18, 2026
Fondamentali al Ago 5, 2026
Intervallo 52 sett.
$6–$11
74% of range
Rating Analisti
BUY
17 analysts
Prezzo Obiettivo
$21
+111% upside
P/E (TTM)
9.7
ROE
-97.6%
Margine di Profitto Netto
30.2%
Informazioni su BioCryst Pharmaceuticals, Inc. - Common Stock Panoramica della società da Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
Leggi di più
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
BCRX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$9.88
Capitalizzazione di Mercato
$2.51B
P/E (TTM)
9.7
EPS (TTM)
$1.21
Ricavi (TTM)
$875M
Rendimento div.
—
ROE
-97.6%
D/E Debito/Patrimonio
0.0
Intervallo 52 sett.
$6 – $11
BCRX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$875M
2016-12-31
→
2025-12-31
EPS
$1.21
2020-12-31
→
2025-12-31
Flusso di cassa libero
$345M
2016-12-31
→
2025-12-31
Margini
30.2%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
BCRX
Mediana dei peer
P/E (TTM)
9.7
97.6
P/S (TTM)
2.9
7.7
P/B
-21.1
8.0
EV / EBITDA
6.5
—
Price / FCF (Prezzo / FCF)
7.3
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
BCRX
Mediana dei peer
Operating Margin (Margine Operativo)
39.0%
—
Net Profit Margin (Margine di Profitto Netto)
30.2%
-51.7%
ROA
52.5%
-44.2%
ROE
-97.6%
-63.5%
ROIC
-282.4%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
BCRX
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
0.0
18.7
Current Ratio (Rapporto corrente)
2.1
4.9
Quick Ratio
1.9
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
BCRX
Mediana dei peer
Revenue YoY (Ricavi YoY)
94.1%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
47.8%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
117.9%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
BCRX
Mediana dei peer
BCRX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
17 analisti
- Acquisto forte 5 29,4%
- Compra 10 58,8%
- Mantieni 2 11,8%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
11 analisti · 2026-08-17
Mediana
$17.00
Media
$20.82
← Sotto tutti i target
$9.88
Basso
$12.00
Alto
$32.00
Target mediano
$17.00
+72,1%
Target medio
$20.82
+110,7%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.02%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $0.30 | $0.12 | 0.18% |
| 31 Marzo 2026 | $-0.09 | $0.05 | -0.14% |
| 31 Dicembre 2025 | $0.01 | $0.04 | -0.03% |
| 30 Settembre 2025 | $0.06 | $0.04 | 0.02% |
| 30 Giugno 2025 | $0.04 | $0.01 | 0.03% |
| 31 Marzo 2025 | $0.00 | $-0.07 | 0.07% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| VERA | — | -10.9 | — | — | -55.9% | — |
| MLYS | $2.96B | -15.8 | — | — | -32.2% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Stato Patrimoniale 27
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Flusso di cassa 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Liquidità e Solvibilità 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 13
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Conto Economico 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | -418,684,000 | 210,176,000 | 209,519,000 | 208,882,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | -436,451,000 | 219,885,000 | 219,886,000 | 215,261,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Stato Patrimoniale 24
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Flusso di cassa 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Redditività 7
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Liquidità e Solvibilità 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Valutazione (TTM) 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $697M | $625M | · | $585M | $535M | $465M | · | $406M | $371M | $331M | · | $314M | $293M | $260M | · | $232M | |
| Net Income TTM | $-625M | $-704M | · | $4M | $-22M | $-62M | · | $-98M | $-160M | $-200M | · | $-207M | $-230M | $-229M | · | $-234M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -3.8 | -3.3 | · | 759.0 | -81.5 | -25.0 | · | -15.5 | -7.5 | -4.9 | · | -6.4 | -5.7 | -6.8 | · | -9.8 | |
| P/S | 3.7 | 3.9 | · | 2.7 | 3.5 | 3.4 | · | 3.9 | 3.4 | 3.2 | · | 4.3 | 4.6 | 6.1 | · | 10.1 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| P / FCF | · | -38.9 | · | · | · | -56.7 | · | · | · | -19.4 | · | · | · | -33.0 | · | · | |
| EV / EBITDA | 26.4 | -3.7 | · | 53.4 | 62.6 | 73.7 | · | 232.9 | 172.6 | -89.7 | · | -125.1 | -71.5 | -59.0 | · | -133.3 | |
| EV / FCF | · | -41.4 | · | · | · | -57.5 | · | · | · | -23.6 | · | · | · | -34.7 | · | · | |
| EV / Revenue | 3.7 | 4.1 | · | 2.7 | 3.5 | 3.4 | · | 4.4 | 4.1 | 3.8 | · | 4.8 | 5.1 | 6.4 | · | 10.0 | |
| Earnings Yield | -26.0% | -30.5% | · | 0.13% | -1.2% | -4.0% | · | -6.5% | -13.3% | -20.5% | · | -15.5% | -17.5% | -14.8% | · | -10.2% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $875M | $451M | $331M | $271M | $157M |
| Margine Operativo % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Utile netto | $264M | $-89M | $-227M | $-247M | $-184M |
| EPS Diluito | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Rapporto corrente | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $345M | $-53M | $-97M | $-163M | $-145M |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 346 filer · $2.1B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 63 (-7 vs trimestre precedente) | 34 (-7 vs trimestre precedente) | 130 (+19 vs trimestre precedente) | 83 (+3 vs trimestre precedente) | +25.9M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 7,51% | Azioni |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 7,21% | Azioni |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 7,16% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 5,39% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 5,29% | Azioni |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 5,23% | Azioni |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 4,89% | Azioni |
| JANUS HENDERSON GROUP PLC | $83.961.589 | 8.814.865 | 3,98% | Azioni |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 3,94% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 3,21% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $53.581.572 | 5.356.880 | 2,54% | Azioni |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 2,52% | Azioni |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,90% | Azioni |
| GOLDMAN SACHS GROUP INC | $35.393.210 | 3.539.321 | 1,68% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,61% | Azioni |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,51% | Azioni |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,37% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $27.161.110 | 2.716.111 | 1,29% | Azioni |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 1,24% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 1,20% | Azioni |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 1,20% | Azioni |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 1,19% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 1,12% | Azioni |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 1,11% | Azioni |
| AQR CAPITAL MANAGEMENT LLC | $21.850.110 | 2.185.011 | 1,04% | Azioni |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,90% | Azioni |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,89% | Azioni |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,88% | Azioni |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,88% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,83% | Azioni |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,83% | Azioni |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,78% | Azioni |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,77% | Azioni |
| JANE STREET GROUP, LLC | $14.267.680 | 1.426.768 | 0,68% | Azioni |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,64% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,57% | Azioni |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,57% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,56% | Azioni |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,53% | Azioni |
| JANE STREET GROUP, LLC | $9.944.130 | 994.413 | 0,47% | Opzione Call |
| Cubist Systematic Strategies, LLC | $9.462.419 | 1.246.696 | 0,45% | Azioni |
| MOORE CAPITAL MANAGEMENT, LP | $8.483.360 | 848.336 | 0,40% | Azioni |
| FMR LLC | $8.062.330 | 806.233 | 0,38% | Azioni |
| BANK OF AMERICA CORP /DE/ | $7.754.020 | 775.402 | 0,37% | Azioni |
| ExodusPoint Capital Management, LP | $7.449.170 | 744.917 | 0,35% | Azioni |
| Man Group plc | $7.324.800 | 732.480 | 0,35% | Azioni |
| Rosalind Advisors, Inc. | $7.215.040 | 721.504 | 0,34% | Azioni |
| Schonfeld Strategic Advisors LLC | $7.108.160 | 710.816 | 0,34% | Azioni |
| BlackRock, Inc. | $5.984.400 | 598.440 | 0,28% | Azioni |
| Elmind Capital, LP | $5.200.000 | 520.000 | 0,25% | Azioni |
| Bridgewater Associates, LP | $4.910.570 | 491.057 | 0,23% | Azioni |
| NAN FUNG TRINITY (HK) LTD | $4.500.000 | 450.000 | 0,21% | Azioni |
| SPHERA FUNDS MANAGEMENT LTD. | $4.220.510 | 422.051 | 0,20% | Azioni |
| Swiss National Bank | $4.152.680 | 415.268 | 0,20% | Azioni |
| Susquehanna Portfolio Strategies, LLC | $4.047.040 | 404.704 | 0,19% | Azioni |
| DAFNA Capital Management LLC | $4.002.480 | 400.248 | 0,19% | Azioni |
| Hudson Bay Capital Management LP | $4.000.000 | 400.000 | 0,19% | Azioni |
| Aquatic Capital Management LLC | $3.628.950 | 362.895 | 0,17% | Azioni |
| DOLIVER CAPITAL ADVISORS, INC. | $3.563.603 | 374.328 | 0,17% | Azioni |
| Assenagon Asset Management S.A. | $3.530.440 | 353.044 | 0,17% | Azioni |
| Kodai Capital Management LP | $3.515.993 | 468.799 | 0,17% | Azioni |
| MACKENZIE FINANCIAL CORP | $3.472.990 | 347.299 | 0,16% | Azioni |
| CITIGROUP INC | $3.467.520 | 346.752 | 0,16% | Azioni |
| Phocas Financial Corp. | $3.405.410 | 340.541 | 0,16% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.238.000 | 323.800 | 0,15% | Opzione Call |
| ALPS ADVISORS INC | $3.179.600 | 317.960 | 0,15% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $3.121.694 | 327.909 | 0,15% | Azioni |
| RHUMBLINE ADVISERS | $2.798.390 | 279.839 | 0,13% | Azioni |
| Rafferty Asset Management, LLC | $2.656.180 | 265.618 | 0,13% | Azioni |
| Point72 Asset Management, L.P. | $2.609.170 | 260.917 | 0,12% | Azioni |
| Nuveen, LLC | $2.599.030 | 259.903 | 0,12% | Azioni |
| NFJ INVESTMENT GROUP, LLC | $2.568.330 | 256.833 | 0,12% | Azioni |
| Nebula Research & Development LLC | $2.567.121 | 286.509 | 0,12% | Azioni |
| WINTON GROUP Ltd | $2.556.000 | 255.600 | 0,12% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2.459.444 | 258.345 | 0,12% | Azioni |
| MARTINGALE ASSET MANAGEMENT L P | $2.425.080 | 242.508 | 0,12% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $2.324.670 | 232.467 | 0,11% | Azioni |
| CITADEL ADVISORS LLC | $2.322.000 | 232.200 | 0,11% | Opzione Call |
| IEQ CAPITAL, LLC | $2.274.210 | 227.421 | 0,11% | Azioni |
| Bank of New York Mellon Corp | $2.251.670 | 225.167 | 0,11% | Azioni |
| D. E. Shaw & Co., Inc. | $2.249.120 | 224.912 | 0,11% | Azioni |
| JUPITER ASSET MANAGEMENT LTD | $2.221.030 | 222.103 | 0,11% | Azioni |
| HUSSMAN STRATEGIC ADVISORS, INC. | $2.100.000 | 210.000 | 0,10% | Azioni |
| PFM Health Sciences, LP | $2.073.570 | 207.357 | 0,10% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.962.800 | 196.280 | 0,09% | Azioni |
| TUDOR INVESTMENT CORP ET AL | $1.951.280 | 195.128 | 0,09% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.853.000 | 185.300 | 0,09% | Opzione Put |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $1.820.161 | 233.354 | 0,09% | Azioni |
| Engineers Gate Manager LP | $1.750.020 | 175.002 | 0,08% | Azioni |
| Squarepoint Ops LLC | $1.747.140 | 174.714 | 0,08% | Azioni |
| QTR Family Wealth, LLC | $1.610.820 | 161.082 | 0,08% | Azioni |
| Gotham Asset Management, LLC | $1.564.210 | 156.421 | 0,07% | Azioni |
| CITADEL ADVISORS LLC | $1.450.000 | 145.000 | 0,07% | Opzione Put |
| Corient Private Wealth LP | $1.429.860 | 142.986 | 0,07% | Azioni |
| NEW YORK STATE COMMON RETIREMENT FUND | $1.386.570 | 138.657 | 0,07% | Azioni |
| Quantinno Capital Management LP | $1.374.530 | 137.453 | 0,07% | Azioni |
| MetLife Investment Management, LLC | $1.356.700 | 135.670 | 0,06% | Azioni |
| PROFUND ADVISORS LLC | $1.340.340 | 134.034 | 0,06% | Azioni |
| Virtus Investment Advisers, LLC | $1.336.640 | 133.664 | 0,06% | Azioni |
| ADAR1 Capital Management, LLC | $1.330.000 | 133.000 | 0,06% | Azioni |
Insider aziendali 51 insider · 21 dirigenti · 30 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 Dicembre 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 Dicembre 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 Febbraio 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 Marzo 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 Dicembre 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 Marzo 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 Maggio 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 06 Aprile 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 Marzo 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 Dicembre 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 Novembre 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 Marzo 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 Dicembre 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 Gennaio 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 Marzo 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 07 Febbraio 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 Marzo 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 Luglio 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 Luglio 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 Luglio 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 Maggio 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Direttore | 11 Giugno 2026 A | 47.177 | 0 | 1 | $-100.285 |
| Theresa Heggie | Direttore | 11 Giugno 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Direttore | 11 Giugno 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Jill C. Milne | Direttore | 11 Giugno 2026 A | 31.938 | 0 | 0 | $0 |
| Steven Frank | Direttore | 11 Giugno 2026 A | 35.459 | 0 | 0 | $0 |
| Steven K Galson | Direttore | 11 Giugno 2026 A | 27.794 | 0 | 0 | $0 |
| Jon P Stonehouse | Direttore | 11 Giugno 2026 A | 1.339.775 | 0 | 0 | $0 |
| Vincent Milano | Direttore | 11 Giugno 2026 A | 108.483 | 0 | 0 | $0 |
| Alan G Levin | Direttore | 11 Giugno 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Direttore | 12 Giugno 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Direttore | 12 Giugno 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Direttore | 12 Giugno 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Direttore | 13 Giugno 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Direttore | 28 Febbraio 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Direttore | 28 Novembre 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Direttore | 20 Giugno 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Direttore | 24 Maggio 2017 A | — | 0 | 0 | $0 |
| Charles A Sanders | Direttore | 29 Febbraio 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Direttore | 02 Maggio 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Direttore | 23 Maggio 2012 A | — | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Direttore | 23 Maggio 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Direttore | 12 Maggio 2011 A | — | 0 | 0 | $0 |
| Beth C Seidenberg | Direttore | 13 Maggio 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Direttore | 13 Maggio 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Direttore | 16 Maggio 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Direttore | 16 Maggio 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Direttore | 18 Marzo 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Direttore | 17 Maggio 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Direttore | 04 Novembre 2003 M | 46.785 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 15 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 depositi | 31 Luglio 2018 | — | Deposito iniziale | — | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 02 Aprile 2018 | — | Deposito iniziale | Investimento passivo | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 depositi | 16 Agosto 2016 | — | Deposito iniziale | — | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 depositi | 23 Ottobre 2012 | — | Deposito iniziale | — | SEC |
| Julian C. Baker, Felix J. Baker ×4 depositi | 13 Ottobre 2011 | — | Deposito iniziale | — | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 depositi | 20 Agosto 2007 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 07 Dicembre 2005 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 07 Dicembre 2005 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 07 Dicembre 2005 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata | 13 Ottobre 2005 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 26 Febbraio 2004 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 25 Febbraio 2004 | — | Deposito iniziale | — | SEC |
| Persona segnalante non divulgata, Persona segnalante non divulgata, Persona segnalante non divulgata | 24 Febbraio 2004 | — | Deposito iniziale | — | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 depositi | 31 Ottobre 2003 | — | Deposito iniziale | — | SEC |
| William W. Featheringill | 14 Febbraio 2002 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 53 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,65% | 1.023.838 SH | 08 Agosto 2026 | Giornaliero |
| BBP · ETFis Series Trust I | 1,93% | 125.015 NS | 30 Aprile 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 1,26% | 1.682 NS | 30 Aprile 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,67% | 381.305 NS | 30 Aprile 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,54% | 612.341 NS | 30 Aprile 2026 | N-PORT |
| CALF · Pacer Funds Trust | 0,41% | 1.556.494 NS | 30 Aprile 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,28% | 364.624 NS | 30 Aprile 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0,25% | 59.894 NS | 31 Maggio 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,24% | 72.535 SH | 08 Agosto 2026 | Giornaliero |
| GSSC · Goldman Sachs ETF Trust | 0,19% | 213.133 NS | 31 Maggio 2026 | N-PORT |
| SMLF · iShares Trust | 0,17% | 758.958 SH | 08 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,16% | 13.830 SH | 08 Agosto 2026 | Giornaliero |
| IBB · iShares Trust | 0,15% | 1.580.105 SH | 08 Agosto 2026 | Giornaliero |
| ESSC · Strategy Shares | 0,15% | 4.183 NS | 30 Aprile 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 08 Agosto 2026 | Giornaliero |
| IWO · iShares Trust | 0,13% | 2.097.061 SH | 08 Agosto 2026 | Giornaliero |
| BIB · ProShares Trust | 0,11% | 9.271 NS | 31 Maggio 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 57.134 NS | 30 Aprile 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,10% | 81.871 NS | 30 Aprile 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 08 Agosto 2026 | Giornaliero |
| ISCG · iShares Trust | 0,07% | 73.787 SH | 08 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,07% | 5.925.076 SH | 08 Agosto 2026 | Giornaliero |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 206.325 SH | 08 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,06% | 97.958 NS | 30 Aprile 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 806.097 NS | 30 Aprile 2026 | N-PORT |
| ITWO · ProShares Trust | 0,05% | 10.652 NS | 31 Maggio 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,05% | 1.154.262 NS | 31 Maggio 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 08 Agosto 2026 | Giornaliero |
| ISCB · iShares Trust | 0,03% | 10.494 SH | 08 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 96.151 NS | 30 Aprile 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 08 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 08 Agosto 2026 | Giornaliero |
| UWM · ProShares Trust | 0,03% | 8.331 NS | 31 Maggio 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 8.425 NS | 31 Maggio 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 08 Agosto 2026 | Giornaliero |
| WSML · iShares Trust | 0,02% | 11.689 SH | 08 Agosto 2026 | Giornaliero |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 9.529 NS | 31 Maggio 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 212 NS | 31 Maggio 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 80.493 NS | 31 Maggio 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 74.317 NS | 30 Aprile 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 72.218 SH | 08 Agosto 2026 | Giornaliero |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,00% | 937 NS | 31 Maggio 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 336.352 SH | 08 Agosto 2026 | Giornaliero |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 141.645 NS | 31 Maggio 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 6.314 NS | 30 Aprile 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 34.873 NS | 30 Aprile 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,00% | 8.956 NS | 30 Aprile 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,00% | 129 NS | 31 Maggio 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 3.019 NS | 30 Aprile 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 08 Agosto 2026 | Giornaliero |